Introduction {#sec1-2055217319894604}
============

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) resulting from an autoimmune attack targeting myelin sheets in the CNS, leading to demyelination, axonal and neuronal injury.^[@bibr1-2055217319894604]^ Natalizumab (Tysabri, Biogen), a recombinant humanised monoclonal antibody that targets α~4~β~1~ and α~4~β~7~ integrins on the surface of leukocytes is regarded as an effective disease-modifying therapy for relapsing--remitting multiple sclerosis (RRMS) that prevents invasion of the CNS through the blood--brain barrier, thus reducing inflammation and preventing the formation of new focal lesions. These effects translate into a significant reduction of relapse rates and disability progression.^[@bibr2-2055217319894604]^ However, treatment with natalizumab has been associated with the development of progressive multifocal leukoencephalopathy (PML), a devastating opportunistic lytic infection of oligodendrocytes in the CNS that is caused by reactivation of the latent human polyomavirus JC virus (JCV).^[@bibr3-2055217319894604]^ JCV seropositivity, longer treatment duration, especially beyond 2 years, and prior treatment with immunosuppressants has been identified as risk factors and are used for clinical guidance.^4^

Poly (ADP-ribose) polymerase 1 (PARP-1) is the most abundant and well-characterised member of the PARP nuclear enzyme superfamily that catalyses the transfer of ADP-ribose units from nicotinamide adenine dinucleotide (NAD+) to a broad panel of acceptor proteins such as histones and transcription factors.^[@bibr5-2055217319894604]^ PARP-1 is involved in a wide range of cellular processes including DNA repair, cell proliferation and death signalling, transcriptional regulation and inflammation.^[@bibr6-2055217319894604],[@bibr7-2055217319894604]^ Diverse studies conducted in the murine experimental autoimmune encephalomyelitis model of MS suggested a potential role for PARP-1 in the pathogenesis of MS,^[@bibr8-2055217319894604][@bibr9-2055217319894604][@bibr10-2055217319894604]--[@bibr11-2055217319894604]^ triggering the development of PARP-1 inhibitors as promising approaches for immunomodulation in MS.^[@bibr12-2055217319894604]^ Besides their potential value for MS treatment, PARP-1 inhibitors have also been suggested as novel therapeutic drugs for PML.^[@bibr13-2055217319894604]^

Here, we examined PARP-1 expression in various lymphocyte subpopulations from untreated and natalizumab-treated MS patients and in patients with natalizumab-associated PML. We report the differential expression of PARP-1 and downstream effectors in T and B cells, together with deregulated PARP-1 expression in patients with PML.

Methods {#sec2-2055217319894604}
=======

Subjects {#sec3-2055217319894604}
--------

Patient characteristics and cohorts are depicted in [Table 1](#table1-2055217319894604){ref-type="table"}. Samples were collected during visits of the patients in the years 2008--2015 and for PML cases in the years 2008--2012. Five different and heterogenous cohorts (except monocyte and B cell cohorts that were homogeneous) were used for the study. Considering the duration of natalizumab treatment as a risk factor for developing PML, we divided our cohorts of natalizumab-treated patients into two groups: treatment duration of 3--24 months and longer than 24 months. A group of 15 natalizumab-treated patients who developed PML was also included in the peripheral blood mononuclear cell (PBMC) cohort. Samples were drawn after PML diagnosis. The JCV serostatus was available from 57 out of 58 natalizumab-treated patients of the PBMC cohort. PML patients were all JCV seropositive (15/15); 10 short-term treated non-PML patients (3--24 months, 10/21) and 10 long-term treated non-PML patients (\>24 months, 10/22) were JCV seropositive. All untreated patients had no immunomodulation in the 6 months before or during the study.

###### 

Characteristics of patients.

![](10.1177_2055217319894604-table1)

  Group                              *N*   Gender F/M   Age (years) mean ± SD   No. of natalizumab infusions mean ± SD   EDSS median (IQR)   No. of relapses in the past 6 months mean ± SEM
  ---------------------------------- ----- ------------ ----------------------- ---------------------------------------- ------------------- -------------------------------------------------
  Cohort for B cell analysis                                                                                                                 
   • Healthy volunteers              12    10/2         41.0 ± 4.09             NA                                       NA                  NA
   • Untreated RRMS                  12    8/4          55.7 ± 3.13             NA                                       3.0 (2.5--3.8)      0.16 ± 0.11
   • Nat 3--24 months                12    10/2         40.5 ± 3.64             14.0 ± 1.97                              3.25 (1.6--3.8)     0.25 ± 0.17
   • Nat \>24 months                 12    9/3          39.2 ± 2.32             66.7 ± 6.60                              2.5 (2.0--3.5)      0
  Cohort for CD4^+^T cell analysis                                                                                                           
   • Healthy volunteers              12    8/4          36.1 ± 2.78             NA                                       NA                  NA
   • Untreated RRMS                  12    9/3          46.8 ± 2.81             NA                                       2.25 (1.5--3.8)     0.08 ± 0.08
   • Nat 3--24 months                12    8/2          42.6 ± 3.93             12.8 ± 2.35                              3.0 (2.0--4.3)      0.33 ± 0.14
   • Nat \>24 months                 12    10/2         39.8 ± 2.23             39.6 ± 1.67                              3.25 (3.0--3.8)     0
  Cohort for CD8^+^T cell analysis                                                                                                           
   • Healthy volunteers              12    8/4          41.4 ± 2.93             NA                                       NA                  NA
   • Untreated RRMS                  12    9/3          47.4 ± 2.98             NA                                       2.0 (1.5--3.2)      0.16 ± 0.11
   • Nat 3--24 months                10    8/2          39.8 ± 3.73             8.7 ± 2.70                               2.5 (1.3--4.0)      0.60 ± 0.26
   • Nat \>24 months                 12    10/2         41.0 ± 2.80             51.1 ± 4.55                              3.0 (2.1--4.5)      0.16 ± 0.16
  Cohort for monocyte analysis                                                                                                               
   • Healthy volunteers              11    9/2          39.4 ± 4.12             NA                                       NA                  NA
   • Untreated RRMS                  12    8/4          55.7 ± 3.13             NA                                       3.0 (2.5--3.8)      0.16 ± 0.11
   • Nat 3--24 months                12    10/2         40.5 ± 3.64             14.0 ± 1.97                              3.25 (1.6--3.8)     0.25 ± 0.17
   • Nat \>24 months                 11    8/3          40.2 ± 2.29             69.0 ± 6.81                              2.5 (2.0--3.5)      0
  Cohort for PBMC analysis                                                                                                                   
   • Healthy volunteers              14    8/6          46.0 ± 2.93             NA                                       NA                  NA
   • Untreated RRMS                  20    14/6         52.1 ± 1.88             NA                                       2.0 (1.7--2.5)      0.05 ± 0.05
   • Nat 3--24 months                21    16/5         40.0 ± 2.79             14.0 ± 1.74                              3.5 (2.7--4.2)      0.35 ± 0.10
   • Nat \>24 months                 22    17/5         40.6 ± 2.20             49.0 ± 3.62                              3.25 (2.5--4.0)     0
   • PML                             15    12/3         45.9 ± 2.22             33.5 ± 3.34                              --                  --

IQR: interquartile range; EDSS: Expanded Disability Status Scale; RRMS: relapsing--remitting multiple sclerosis; Nat: natalizumab; PBMC: peripheral blood mononuclear cell; PML: progressive multifocal leukoencephalopathy.

Standard protocol approvals, registrations and patient consents {#sec4-2055217319894604}
---------------------------------------------------------------

Written informed consent was obtained from all patients and healthy donors spontaneously recruited. The study was approved by the cantonal institutional review board of Basel City and Basel Country.

Cell separation {#sec5-2055217319894604}
---------------

PBMCs were isolated from ethylenediamine tetraacetic acid (EDTA) anticoagulated venous blood by density gradient centrifugation (Lymphoprep; Axon Lab, Switzerland). CD4^+^T/CD8^+^T/CD14^+^T and B cell subpopulations were separated from PBMCs using MACS technology (positive isolation using CD4, CD8, and CD14 microbeads, human, B-cell negative enrichment kit II; Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) according to the manufacturer's instructions. Purity of isolated CD4^+^T (97.9% ± 0.21), CD8^+^T (96.4% ± 0.42), CD14^+^ (95.9% ± 0.6) and B cells (97.7% ± 0.36) was analysed with an Attune focusing flow cytometer (Applied Biosystems, Darmstadt, Germany).

RNA isolation {#sec6-2055217319894604}
-------------

QIAzol (QIAgen AG, Hombrechtikon, Switzerland) was used to lyse PBMCs and isolated cell subpopulations. Total RNA (including miRNA) was extracted using an miRNeasy mini kit (QIAgen) according to the manufacturer's protocol.

Messenger RNA expression analysis {#sec7-2055217319894604}
---------------------------------

Total RNA was reverse-transcribed using qScript XLT cDNA SuperMix (Quantabio) according to the manufacturer's protocol. cDNA was used as a template for the real-time reverse transcriptase polymerase chain reaction (RT-PCR) based on the 5′ nuclease chemistry with ABI PRISM 7500 sequence detection system (Applied Biosystems, Switzerland), using the following assay-on-demand reagents (Applied Biosystems): *PARP1 (*Hs 00242302_m1); *TGFBR1 (*Hs 00610318_m1); *TGFBR2 (*Hs 00234253_m1); *BCL6 (*Hs 00153368_m1). As previously reported,^[@bibr14-2055217319894604]^ PUM1 (Hs 00472881_m1) was used as a reference for normalisation and relative expression analyses. The comparative cycle threshold method (Applied Biosystems) was used for calculations of relative quantitation of targets.

Data and statistical analysis {#sec8-2055217319894604}
-----------------------------

GraphPad Prism software (La Jolla, CA, USA) was used for statistical analysis. For the various group comparisons the non-parametric Mann--Whitney test was applied. *P* \< 0.05 was considered significant. Correlations between expressions were assessed using Spearman's non-parametric correlations.

Results {#sec9-2055217319894604}
=======

Natalizumab restores deregulated PARP-1 expression in T-cell subsets but not in B cells {#sec10-2055217319894604}
---------------------------------------------------------------------------------------

PARP-1 mRNA expression was assessed in CD4^+^T, CD8^+^T, B cells and CD14^+^ monocytes from different cohorts of controls and study patients. Interestingly, PARP-1 was significantly upregulated in untreated RRMS patients compared to healthy volunteers in all tested T and B-cell subsets ([Figure 1(a--c)](#fig1-2055217319894604){ref-type="fig"}). In contrast, PARP-1 expression was downregulated in CD4^+^T ([Figure 1(a)](#fig1-2055217319894604){ref-type="fig"}) and CD8^+^T ([Figure 1(b)](#fig1-2055217319894604){ref-type="fig"}) cells of natalizumab-treated patients. Downregulation was observed already after short-term treatment. In B cells, however, sustained upregulation of PARP-1 was observed under natalizumab therapy irrespective of treatment duration ([Figure 1(c)](#fig1-2055217319894604){ref-type="fig"}). In monocytes, only a trend for upregulation of PARP-1 expression in untreated RRMS patients compared to healthy volunteers was found ([Figure 1(d)](#fig1-2055217319894604){ref-type="fig"}).

![Expression of poly (ADP-ribose) polymerase 1 (PARP-1) mRNA in CD4^+^T, CD8^+^T, B cells and monocytes. Transcriptional expression of PARP-1 was analysed with real-time reverse transcriptase polymerase chain reaction in CD4^+^T (a), CD8^+^T cells (b), B cells (c) and monocytes (d) from healthy volunteer, untreated patients and natalizumab-treated patients (3--24 months or \>24 months). Relative expression levels (median with interquartile range) are depicted. \*\*\*\**P* \< 0.0001; \*\*\**P* \< 0.001; \*\**P* \< 0.01; \**P* \< 0.05.](10.1177_2055217319894604-fig1){#fig1-2055217319894604}

Deregulated TGFBR expression in CD4^+^T and B cells {#sec11-2055217319894604}
---------------------------------------------------

PARP-1 has been suggested to regulate TGFBR expression negatively in T cells.^[@bibr15-2055217319894604]^ We explored TGFBR1 and TGFBR2 expression in the T and B-cell subsets of our cohorts of patients and controls. In CD4^+^T cells, no significant differences were observed in TGFBR1 mRNA expression levels between the four groups ([Figure 2(a)](#fig2-2055217319894604){ref-type="fig"}, left panel). Interestingly, PARP-1 upregulation correlated with significant downregulation of TGFBR2 in CD4^+^T cells from untreated MS patiens versus healthy volunteers ([Figure 2(a)](#fig2-2055217319894604){ref-type="fig"}, right panel) (*r* = --0.60; *P* = 0.002). However, in contrast to the restored PARP-1 mRNA levels in patients treated with natalizumab, sustained downregulation of TGFBR2 was observed under treatment, although significance was lost in the long-term treated group, suggesting a possible delay in the restoration of TGFBR2 mRNA levels. In B cells, PARP-1 upregulation was associated with both TGFBR1 and TGFBR2 downregulation (*P* = 0.051 and *P* = 0.038, respectively) in untreated patients versus healthy volunteers ([Figure 2(b)](#fig2-2055217319894604){ref-type="fig"}). Long-term treatment with natalizumab increased TGFBR1 expression significantly ([Figure 2(b)](#fig2-2055217319894604){ref-type="fig"}, left panel) contrasting to TGFBR2 mRNA expression levels that remained downregulated under therapy ([Figure 2(b)](#fig2-2055217319894604){ref-type="fig"}, right panel). No significant differential expression of TGFBR1 and TGFBR2 was detected in CD8^+^T cells (data not shown).

![Expression of TGFBR1 and TGFBR2 mRNA in CD4^+^T and B cells. Transcriptional expressions of TGFBR1 (left panels) and TGFBR2 (right panels) were analysed with real-time reverse transcriptase polymerase chain reaction in CD4^+^T (a) and B cells (b) from healthy volunteers, untreated and natalizumab-treated patients (3--24 months; \>24 months). Relative expression levels (median with interquartile range) are depicted. \*\*\**P* \< 0.001; \*\**P* \< 0.01, \**P* \< 0.05; ns: not significant.](10.1177_2055217319894604-fig2){#fig2-2055217319894604}

Differential expression of B-cell lymphoma 6 (BCL6) in B and CD8^+^T cells from untreated and natalizumab-treated patients {#sec12-2055217319894604}
--------------------------------------------------------------------------------------------------------------------------

PARP-1 has been proposed to play an important role in switching off BCL6 transcription in B cells.^[@bibr16-2055217319894604]^ In our cohort, in parallel to the uncovered PARP-1 upregulation, a trend for downregulation of BCL6 was observed in untreated and both groups of natalizumab-treated patients ([Figure 3(a)](#fig3-2055217319894604){ref-type="fig"}). Notably, significant lower expression of BCL6 mRNA was detected in samples from patients with long-term therapy. We further extended our analyses to T-cell subsets. In CD4^+^T cells, where BCL6 was shown to play a critical role for regulatory T cell (Treg)-mediated control of T helper type 2 inflammation,^[@bibr17-2055217319894604]^ no significant difference was found in our cohort of patients (data not shown). In contrast, in CD8^+^T cells, BCL6 expression levels correlated with PARP-1 expression, with significant downregulation in untreated patients compared to healthy volunteers (*r* = --0.51; *P* = 0.021) and restored BCL6 expression in natalizumab-treated patients (*r* = --0.61; *P* = 0.002) ([Figure 3(b)](#fig3-2055217319894604){ref-type="fig"}).

![Expression of BCL6 mRNA in B cells and CD8^+^T cells. Transcriptional expression of BCL6 was analysed with real-time reverse transcriptase polymerase chain reaction in B cells (a) and CD8^+^T cells (b) from healthy volunteers, untreated and natalizumab-treated patients (3--24 months; \>24 months). Relative expression levels (median with interquartile range) are depicted. \*\*\**P* \< 0.001; \*\**P* \< 0.01; \**P* \< 0.05; ns: not significant.](10.1177_2055217319894604-fig3){#fig3-2055217319894604}

PARP1/TGFBR deregulation in PML {#sec13-2055217319894604}
-------------------------------

Regarding the reported suppressive effect of a PARP-1 inhibitor on JCV replication,^[@bibr13-2055217319894604]^ we further expanded our investigation of PARP-1 expression to samples from patients with natalizumab-associated PML. The analysis was performed on PBMCs due to the limitation of sample volume. A total of 15 PML patients whose natalizumab treatment duration varied from 17 to 62 months were included in the study. In contrast to the MS-related upregulation of PARP-1 in B and T-cell subsets, no significant difference was found in PBMCs of untreated and control groups, probably reflecting the heterogeneity of the PBMC mixture ([Figure 4(a)](#fig4-2055217319894604){ref-type="fig"}). Also, natural killer cells, which were not studied, may contribute to the expression in PBMCs. The upregulation of PARP-1 mRNA expression was also detected in long-term natalizumab-treated patients. Importantly, a higher expression of PARP-1 was detected in patients with PML. TGFBR1 and TGFBR2 were downregulated in long-term treated patients, in parallel with the expression levels of PARP-1 ([Figure 4(b)](#fig4-2055217319894604){ref-type="fig"}, left and right panel, respectively). Strikingly lower expressions of TGFBR1 and TGFBR2 were found in PML patients, thereby being in line with the high PARP-1 expression levels.

![Expression of poly (ADP-ribose) polymerase 1 (PARP-1), TGFBR1 and TGFBR2 mRNA in peripheral blood mononuclear cells (PBMCs). Transcriptional expression of PARP-1 (a), TGFBR1 ((b), left panel) and TGFBR2 ((b), right panel) were analysed with real-time reverse transcriptase polymerase chain reaction in PBMCs from healthy volunteers, untreated, natalizumab-treated patients (3--24 months; \>24 months) and natalizumab-associated progressive multifocal leukoencephalopathy (PML) patients. Relative expression levels (median with interquartile range) are depicted. \*\*\*\**P* \< 0.0001; \*\*\**P* \< 0.001; \*\**P* \< 0.01; \**P* \< 0.05; ns: not significant.](10.1177_2055217319894604-fig4){#fig4-2055217319894604}

Discussion {#sec14-2055217319894604}
==========

Growing evidence supports a significant role for PARP-1 in neurological diseases.^[@bibr18-2055217319894604]^ In the field of neuroimmunology, most data were acquired from experimental animal models.^[@bibr12-2055217319894604]^ In contrast, only few studies have been conducted using human MS samples. PARP-1 activation has been detected in apoptotic oligodendrocytes in MS lesions.^[@bibr19-2055217319894604]^ In a study performed on peripheral blood monocytes of RRMS patients and secondary progressive multiple sclerosis (SPMS), Farez and colleagues showed that PARP-1 enzymatic activity was significantly higher in patients with SPMS.^[@bibr10-2055217319894604]^ Here, we report for the first time higher expression of PARP-1 in lymphocyte subsets from RRMS patients compared to healthy volunteers. Noteworthy, higher PARP-1 expression was detected in CD4^+^T, CD8^+^T and B cells, whereas no significant increase was found in CD14^+^ monocytes, suggesting a possible specific effect on common lymphoid progenitors.

PARP-1 appears as an important regulator of TGFBR expression and transforming growth factor beta (TGF-β) signalling. In fact, increased expression of TGFBR1 and TGFBR2 were found in CD4^+^ T cells from PARP-1^--/--^ mice.^[@bibr15-2055217319894604]^ In our cohort of human CD4^+^T cell samples, increased PARP-1 expression in untreated patients correlated with decreased expression of TGFBR2 but not TGFBR1. Zhang and colleagues proposed distinct underlying mechanisms of negative regulation of TGFBR1 and TGFBR2 expressions by PARP-1, involving on one side a selective binding of PARP-1 to the promoter of TGFBR2 and on the other side an inhibition of TGBFR1 expression mediated by PARP-1 enzymatic activity.^[@bibr15-2055217319894604]^ Such divergent or additional/compensatory mechanisms might be involved in the differential effect of PARP-1 on the expression of TGFBR1 and TGFBR2 in our CD4^+^T samples. Significant downregulation of TGFBR2 expression in untreated RRMS patients compared to healthy volunteers was previously found in another study from our lab using different CD4^+^T cell samples.^[@bibr20-2055217319894604]^ These findings may contribute to a better understanding of the pivotal role of TGF-β signalling in the regulation of immune responses. Hence, Li and colleagues reported lethal inflammation associated with T-cell activation in mice with T-cell-specific deletion of TGFBR2.^[@bibr21-2055217319894604]^ Importantly, deregulation of TGF-β signalling, a critical regulator of the development and function of Tregs, might contribute to the impaired immunoregulatory function of Tregs in MS.^[@bibr22-2055217319894604],[@bibr23-2055217319894604]^ In parallel, growing evidence is supporting an important role for PARP-1 in the regulation of Treg differentiation and function. Hence, Nasta and colleagues reported increased Foxp3^+^ regulatory T cells in PARP-1 deficiency.^[@bibr24-2055217319894604]^ More recently, Luo and colleagues suggested that PARP-1 negatively regulates the immunosuppressive function of Treg cells at the post-translational level by way of FOXP3 poly (ADP-ribosyl)ation.^[@bibr25-2055217319894604]^ Collectively, these data suggest a potential important impact of the deregulation of the PARP-1/TGFBR axis on T-cell function in MS.

In B cells, which are also central players of the immune cascades triggering CNS inflammation,^[@bibr26-2055217319894604],[@bibr27-2055217319894604]^ deregulation of PARP-1/TGFBR signalling might also contribute to MS disease activity. In fact, using PARP-1-deficient mice, Ambrose et al. unravelled an essential role of PARP-1 in normal T-cell-dependent antibody responses and the regulation of isotype expression.^[@bibr28-2055217319894604]^ In mice, B-cell-specific deletion of TGFBR2 highlighted the important role of TGFBR signalling in controlling B-cell homeostasis and responses, notably IgG production.^[@bibr29-2055217319894604]^ In patients' B cells, unlike in T cells, deregulation of PARP-1/TGFBR signalling was observed both in untreated patients and in natalizumab-treated patients. Considering the proposed critical regulatory role of B cells in the immune response that controls JCV infection,^[@bibr30-2055217319894604]^ these data might be of importance in the setting of natalizumab-induced PML development where strikingly overexpressed PARP-1/TGFBR signalling was detected.

Deregulated expression of BCL6 in B cells might also contribute to MS disease pathomechanisms. In fact, BCL6 functions as a transcriptional repressor that impairs premature B-cell activation/differentiation^[@bibr31-2055217319894604]^ and plays a critical role in the development of a diverse primary B-cell repertoire.^[@bibr32-2055217319894604]^ In CD8^+^T cells, considering the critical role of BCL6 in the generation and maintenance of activated memory CD8^+^T cells,^[@bibr33-2055217319894604]^ the downregulation of BCL6 in untreated patients could possibly be involved in the reported deficiency of CD8^+^T effector memory T cells in MS.^[@bibr34-2055217319894604]^ BCL6 was also shown to control granzyme B expression in murine effector CD8^+^T cells.^[@bibr35-2055217319894604]^ In our patient CD8^+^T cells, no significant change in the expression of granzyme B was detected (data not shown).

Conclusions {#sec15-2055217319894604}
===========

Our data support a potential impact of PARP-1 deregulation in MS and treatment-associated PML pathomechanisms, therefore strengthening further the proposed PARP-1 inhibition approach as a novel therapy for MS. However, considering the primary function of PARP-1 in DNA damage detection and repair, the use of PARP-1 inhibitors as therapy for inflammatory diseases requires caution due to the risk of genomic instability.
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